<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1371/journal.pone.0069773</dc:identifier><dc:language>eng</dc:language><dc:creator>Abian, O.</dc:creator><dc:creator>Vega, S.</dc:creator><dc:creator>Sancho, J.</dc:creator><dc:creator>Velazquez-Campoy, A.</dc:creator><dc:title>Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus</dc:title><dc:identifier>ART-2013-82460</dc:identifier><dc:description>The nonstructural protein 3 (NS3) from the hepatitis C virus processes the non-structural region of the viral precursor polyprotein in infected hepatic cells. The NS3 protease activity has been considered a target for drug development since its identification two decades ago. Although specific inhibitors have been approved for clinical therapy very recently, resistance-associated mutations have already been reported for those drugs, compromising their long-term efficacy. Therefore, there is an urgent need for new anti-HCV agents with low susceptibility to resistance-associated mutations. Regarding NS3 protease, two strategies have been followed: competitive inhibitors blocking the active site and allosteric inhibitors blocking the binding of the accessory viral protein NS4A. In this work we exploit the intrinsic Zn+2-regulated plasticity of the protease to identify a new type of allosteric inhibitors. In the absence of Zn+2, the NS3 protease adopts a partially-folded inactive conformation. We found ligands binding to the Zn+2-free NS3 protease, trap the inactive protein, and block the viral life cycle. The efficacy of these compounds has been confirmed in replicon cell assays. Importantly, direct calorimetric assays reveal a low impact of known resistance-associated mutations, and enzymatic assays provide a direct evidence of their inhibitory activity. They constitute new low molecular-weight scaffolds for further optimization and provide several advantages: 1) new inhibition mechanism simultaneously blocking substrate and cofactor interactions in a non-competitive fashion, appropriate for combination therapy; 2) low impact of known resistance-associated mutations; 3) inhibition of NS4A binding, thus blocking its several effects on NS3 protease.</dc:description><dc:date>2013</dc:date><dc:source>http://zaguan.unizar.es/record/63302</dc:source><dc:doi>10.1371/journal.pone.0069773</dc:doi><dc:identifier>http://zaguan.unizar.es/record/63302</dc:identifier><dc:identifier>oai:zaguan.unizar.es:63302</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA/B01</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/DGA/B89</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/DGA/PI044-09</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/FIS/PI10-00186</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/BFU2010-16297</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/BFU2010-19451</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/PTA2009-2341-I</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/UZ/UZ2009-BIO-05</dc:relation><dc:identifier.citation>PLoS One 8, 7 (2013), e69773 [10 pp]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>